Overview

COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada

Status:
Not yet recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
Older adults are at the highest risk of complications and severe illness for 2019-nCoV infections. Hydroxychloroquine (HCQ), an emerging chemoprophylaxis, which holds clinical and mechanistic plausibility, will help to reduce disease incidence and mitigate disease severity across in-patient settings. This study is designed to assess the safety and efficacy of post-exposure prophylaxis with hydroxychloroquine (HCQ) for the prevention of Coronavirus Infectious Disease-19 (COVID-19) in high-risk older individuals in long-term and specialized care.
Phase:
Phase 3
Details
Lead Sponsor:
Lawson Health Research Institute
Treatments:
Hydroxychloroquine